

Cost of illness in patients with psoriasis and psoriatic arthritis. COEPSO Study

Llamas-Velasco M¹, Castañeda S¹, Sánchez-Pérez J¹, Vicente-Rabaneda EF¹, Pardo J², Cabeza-Martínez R³, Miranda Fontes M⁴, Márquez J⁵, Calvo-Alén J⁶, Armesto S⁷, Belinchón I⁸, Gómez A⁹, Miranda MD¹⁰, Martínez Pardo S¹¹, Merino L¹², Casado MA¹³, Amaro A¹³, Ordovás M¹³, Yébenes M¹³, Casado A¹³, COEPSO Study Group

¹ Hospital Universitario de La Princesa, IIS-Princesa, Universidad Autónoma, Madrid, Spain; ² Hospital General Universitario Santa Lucía, Cartagena, Spain; ³ Hospital Universitario Puerta de Hierro de Majadahonda, Madrid, Spain; ⁴ Hospital Universitario Río Hortega, Valladolid, Spain; ⁵ Hospital General de Jerez de la Frontera, Cádiz, Spain; ⁶ Hospital Universitario Araba, Vitoria, Spain; ⁷ Hospital Universitario Marqués de Valdecilla, Santander, Spain; ⁸ Hospital General Universitario de Alicante, Spain; ⁹ Hospital Universitario Infanta Sofía, Madrid, Spain; ¹⁰ Hospital General San Agustín de Linares, Jaén, Spain; ¹¹ Hospital Mutua de Terrassa, Barcelona, Spain; ¹² Hospital San Pedro, Logroño, Spain; ¹³ Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain

INTRODUCTION

- Psoriasis (Ps) and Psoriatic arthritis (PsA) are chronic diseases affecting skin (Blasco AJ., 2009) and musculoskeletal system (Gladman D., 2005), respectively.
- Ps and PsA have a major impact on patients' health-related quality of life (Papoutsaki M., 2013). Besides, it is important to ensure that patients make decisions that are consistent with their needs, preferences, and values. Assessing patients' preferences about their treatments is important to develop measures adapted to patient needs and to improve healthcare quality (Castañeda S., ISPOR 2018; Llamas-Velasco M., ISPOR 2018).
- Ps and PsA are associated with a substantial economic impact (Feldman SR., 2014, Gonzalez-Álvaro I., 2015) and have implications from a health management perspective.
- The severity of these diseases was associated with higher costs in both diseases (Burgos-Pol R., 2016).

OBJECTIVE

The aim of this study was to describe the economic burden of out-of-pocket and indirect resources of patients with Ps, PsA or both manifestations simultaneously (PsA+Ps) in Spain.

METHODS

- The COEPSO Study:
 - Was an observational, retrospective, cross-sectional study performed in 22 Spanish centres (17 Dermatology and 14 Rheumatology Services).
 - The inclusion of patients was initiated in February 2017 and finished in February 2018.
 - Included moderate to severe Ps and PsA patients (with or without Ps), naïve to biological therapies.
 - The information was collected dually through a case report form filled out by the investigators and a telephone survey administered to the patients.
- The following costs related to Ps, PsA and PsA+Ps during the previous year to the COEPSO study were considered:
 - Out-of-pocket costs: Home care, physical adaptations (in home or vehicle), private health professionals and alternative therapists (dermatology, medical herbalist, acupuncturist, homoeopath, other) non-reimbursed and non-pharmaceutical therapies (shampoo and gel, creams, other).
 - Indirect costs: Loss of productivity (number of sick leaves and length).
 - Total costs: Out-of-pocket and indirect costs.
- Unitary costs (€, 2018) were obtained:
 - Out-of-pocket costs: specified directly by patients.
 - Loss of productivity cost by means of average salaries based on occupations specified by patients (NSI: National Statistics Institut, 2015).

RESULTS

- Baseline characteristics are shown in Table 1:
 - Three hundred eighteen patients were included
 - Mean age of all patients in the study was 48.7 years
 - 51.3% were males
 - Metabolic syndrome was the most frequent comorbidity in all groups

Table 1. Sociodemographic and clinic characteristics of the patients included in the COEPSO Study


Patient group, n	Ps 196	PsA 43	PsA+Ps 79
Mean age, years (SD)	45.93 (11.50)	50.51 (11.25)	49.77 (10.27)
Gender, n (%)			
Male	96 (49)	22 (51)	45 (57)
Female	100 (51)	21 (49)	34 (43)
Patients with metabolic syndrome, n (%)	43 (21.94)	6 (13.95)	19 (24.05)
Time from diagnosis to study inclusion, years (SD)	17.49 (12.85)	5.13 (4.32)	Patients with Ps 16.86 (12.16) Patients with PsA 7.81 (6.64)

Ps: Psoriasis; PsA: Psoriatic Arthritis; PsA+Ps: Psoriasis + Psoriatic Arthritis; SD: Standard Deviation

RESULTS

- The average annual out-of-pocket cost per patient was €749.57 (SD 2,393.77), €750.50 (SD 1,641.82) and €1,247.56 (SD 4,467.19) for Ps, PsA and PsA+Ps, respectively (Figure 1).
- The average annual indirect cost per patient was €293.14 (SD 2,855.27), €387.35 (SD 2,409.63) and €582.71 (SD 3,842.12) for Ps, PsA and PsA+Ps, respectively (Figure 1).
- The average annual total cost per patient was €1,042.71 (SD 3,817.55), €1,137.84 (SD 3,070.39) and €1,830.26 (SD 5,835.81) for Ps, PsA and PsA+Ps, respectively (Figure 1).

Figure 1. Anual out-of-pocket, indirect and total cots per patient (€)



Ps: Psoriasis; PsA: Psoriatic Arthritis, PsA+Ps: Psoriasis + Psoriatic Arthritis

Table 2. Percentage of total cost

Patient group	Ps	PsA	PsA+Ps
Out-of-pocket costs	71.89%	65.96%	68.16%
Indirect costs	28.11%	34.04%	31.84%

Ps: Psoriasis; PsA: Psoriatic Arthritis, PsA+Ps: Psoriasis + Psoriatic Arthritis

CONCLUSIONS

- Total costs in patients with Ps and PsA were similar.
- Patients with combined PsA+Ps had higher annual total cost (out-of-pocket and indirect costs) than patients who only had one of these manifestations separately (75.5% and 60.9% above patients with Ps and PsA, respectively).

*COEPSO Study Group

- Castañeda, Santos* / Llamas-Velasco, María del Mar* / Vicente-Rabaneda, Esther / Sánchez-Pérez, Javier (Hospital Universitario de La Princesa)
- Ara, Mariano / Delgado, Concepción / Rivera, Álvaro / Del Río, M^a Pilar (Hospital Universitario Lozano Blesa)
- Agarón, Ángel / Martín, Isabel (Hospital Universitario de Getafe)
- Armesto, Susana / Marcellán, María (Hospital Universitario Marqués de Valdecilla)
- Belinchón, Isabel / Betilloch, Isabel (Hospital Gral. Universitario de Alicante)
- Belmonte, Miguel Ángel / Pitarch, Ana / Armengot, Miquel / Cónesa, Arantxa (Hospital Gral. Universitario de Castellón)
- Calvo, Jaime / Jiménez, Juan Ramón de Dios (Hospital Universitario de Araba)
- Cebrián, Laura / Silvente, Catiana (Hospital Universitario Infanta Leonor)
- Chamizo, Eugenio / Pardo, Ana M^a (Hospital de Mérida)
- García, Mercedes / Martínez, Silvia / Curcó, Neus / Rusiñol, María (Hospital Universitari Mutua de Terrassa)
- García, Rosa / Herrera, Enrique / Sánchez, Cristina (Hospital Virgen de la Victoria)
- Juan Antoni / Melia Catalina (Hospital Son Llatzer)
- López, Eduardo / Guhl, Guillermo (Hospital Clínico San Carlos)
- López-Estebaranz, José Luis (Hospital Universitario Fundación Alcorcón)
- López, Juan Antonio / Merino, Leticia (Complejo Hospitalario San Millán San Pedro)
- Marquez Juan (Hospital de Especialidades de Jerez de la Frontera)
- Miranda, M^a Dolores / Ocaña, M^a José (Hospital San Agustín de Linares)
- Muñoz, Santiago / Gómez, Alejandro (Hospital Universitario Infanta Sofía)
- Pardo, José (Hospital Gral. Universitario Santa Lucía)
- Pozo, Tomás / Miranda Fontes, Mercedes (Hospital Universitario Río Hortega)
- Raya, Enrique / Ruiz, José Carlos / Notario, Irene / Caro, Cristina (Complejo Hospitalario Universitario de Granada)
- Roustan, Luis / Cabeza-Martínez, Rita (Hospital Universitario Puerta de Hierro)

*Principal Investigators

REFERENCES

- Blasco AJ, Lázaro P, Ferrández C, García-Díez A, Liso J. Eficiencia de los agentes biológicos en el tratamiento de la psoriasis moderada-grave. *Actas Dermosifiliogr.* 2009;100:792-803.
- Burgos-Pol R, Martínez-Sesmero JM, Ventura-Cerdá JM, Elías I, Caloto MT, Casado MA. The Cost of Psoriasis and Psoriatic Arthritis in 5 European Countries: A Systematic Review. *Actas Dermosifiliogr.* 2016;107(7):577-590.
- Castañeda S, Vicente-Rabaneda EF, Calvo-Alén J, Gómez A, Miranda MD, Martínez Pardo S, Merino L, Llamas-Velasco M, Casado A, Amaro A, Sabater E, Yébenes M, COEPSO Study Group. Patient's preferences for treatment of psoriatic arthritis based on a discrete choice experiment. Results of the COEPSO study. 21st Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Barcelona. 10-14 nov 2018.
- Feldman SR, Burupakdee C, Gala S, Nanavaty M, MallyaUG. The economic burden of psoriasis: A systematic literature review. *Expert Rev Pharmacoecon Outcomes Res.* 2014;14:685-705.
- Gladman D, Antoni C, Mease P, Clegg D, Nash P. Psoriatic arthritis: Epidemiology, clinical features, course, and outcome. *Ann Rheum Dis.* 2005;64 Suppl 2:i14-7-6.
- González-Álvaro I, Martínez-Fernandez C, Dorantes-Calderon B, García-Vicuña R, Hernández-Cruz B, Herrero-Ambrosio A, et al. Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization inpatients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. *Rheumatology (Oxford).* 2015;54:1200-9.
- Llamas-Velasco M, Sánchez-Pérez J, Pardo J, Cabeza-Martínez R, Miranda Fontes M, Márquez J, Armesto S, Belinchón I, Castañeda S, Casado A, Amaro A, Yébenes M, Sabater E, COEPSO Study Group. Patient's preferences for psoriasis treatment based on a discrete choice experiment. COEPSO study. 21th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Barcelona. 10-14 nov 2018.
- Papoutsaki M, Costanzo A. Treatment of psoriasis and psoriatic arthritis. *BioDrugs.* 2013;27 Suppl 1:3-12.

Designed by



Presented at ISPOR Europe 2019
2-6 November 2019 | Copenhagen, Denmark

